Novartis: FDA approves neglected tropical disease drug
(CercleFinance.com) - The US Food and Drug Administration has approved Novartis' tretment for fascioliasis, a neglected tropical disease.
The FDA has approved Egaten for the treatment of fascioliasis in patients six years of age and older, making the medicine the only FDA-approved drug for people with this disease.
Fascioliasis, commonly known as liver fluke infestation, infects 2.4 million people worldwide, with an additional 180 million at risk of infection.
It is spread by two species of parasitic flatworms that can infect humans following ingestion of larvae in contaminated water or food.
Novartis said it plans to facilitate broader access to the drug not only in the US, but also in affected countries worldwide.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The FDA has approved Egaten for the treatment of fascioliasis in patients six years of age and older, making the medicine the only FDA-approved drug for people with this disease.
Fascioliasis, commonly known as liver fluke infestation, infects 2.4 million people worldwide, with an additional 180 million at risk of infection.
It is spread by two species of parasitic flatworms that can infect humans following ingestion of larvae in contaminated water or food.
Novartis said it plans to facilitate broader access to the drug not only in the US, but also in affected countries worldwide.
Copyright (c) 2019 CercleFinance.com. All rights reserved.